



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

5

Complete If Known

Application Number	09/829,031
Filing Date	April 9, 2001
First Named Inventor	Browning et al.
Group Art Unit	1644
Examiner Name	Bao Qun Li
Attorney Docket Number	A063 US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BQ	ca	Duzgunes et al., Journal of Cell. Biochem. Abst. Suppl. 16E 77 (1992); "Liposome Targeting to HIV-Infected Cells via Recombinant Soluble CD4 and CD4-IgG Immunoadhesin"	
	cb	Abe, Yashuhito et al, Lymphokine and Cytokine Research, Vol. 11, No. 2, pp. 115-121 (1992); "Studies of Membrane-Associated and Soluble (Secreted) Lymphotoxin in Human Lymphokine-Activated T-Killer Cells in Vitro"	
	cc	Arulanandam, Antonio et al., J. Exp. Med, Vol. 177, pp. 1439-1450 (1993); "A Soluble Multimeric Recombinant CD2 Protein Identifies CD48 as a Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands during the Evolution of Humans and Mice"	
	cd	Bethell, Delia et al., Journal of Infectious Diseases, Vol. 177, pp. 778-782 (1998); "Pathophysiologic and Prognostic Role of Cytokines in Dengue Hemorrhagic Fever"	
	ce	Beutler, B. et al., Science, Vol. 229, pp. 869-871 (1985); "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin"	
	cf	Browning, Jeffrey et al., Jour. of Immunology, Vol. 154, pp. 33-46 (1995); "Characterization of Surface Lymphotoxin Forms Use of Specific Monoclonal Antibodies and Soluble Receptors"	
	cg	Browning, Jeffrey et al., Cell, Vol. 72, pp. 847-856 (1993); "Lymphotoxin Beta, a Novel Member of the TNF Family that Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface"	
	ch	Chaplin, D. et al., Curr. Opin. in Immunology, Vol. 10, pp. 289-297 (1998); "Cytokine regulation of secondary lymphoid organ development"	
	ci	Crowe, Paul et al., Jour. of Immunological Methods, Vol. 168, pp. 79-89 (1994); "Production of lymphotoxin (LT-alpha) and a soluble dimeric form of its receptor using the baculovirus expression system"	
	cj	Crowe, Paul et al., Science, Vol. 264, pp. 707-710 (1994); "A Lymphotoxin-beta-Specific Receptor"	
	ck	Eppstein, Deborah et al, Proc. Natl Acad. Sci. USA, Vol. 82, pp. 3688-3692 (1985) Cell Biology; "Biological activity of a liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor"	

Examiner
Signature

Bao Qun Li

Date


Considered

09/15/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

5

Complete If Known

Application Number	09/829,031
Filing Date	April 9, 2001
First Named Inventor	Jeffrey Browning et al.
Group Art Unit	1644
Examiner Name	Bao Qun Li
Attorney Docket Number	A063

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BAC	cl	Fagerstam, Lars et al., Handbook of Affinity Chromatography, Marcel Dekker, Inc., NY, pp. 229-252 (1993); Surface Plasmon Resonance Detection in Affinity Technologies.	
	cm	Force, Walker et al., Journal of Immunology, Vol 155, pp. 5280-5288 (1995); "Mouse Lymphotoxin-beta Receptor Molecular Genetics, Ligand Binding, and Expression"	
	cn	Hober, Didier et al., Am. Jour. Trop. Med. Hyg., Vol. 48, No. 3, pp. 324-331 (1993); "Serum Levels of Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in Dengue-Infected Patients"	
	co	Hwang, Karl et al., Proc. Natl. Acad. Sci. USA, Vol. 77, No. 7, pp. 4030-4034 (1980); "Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study"	
	cp	Lacy, Mark et al., Adv. in Pediatric Infectious Diseases, Vol. 12, pp 21-53 (1997); "Viral Hemorrhagic Fevers"	
	cq	Lane, Peter et al., Eur. Journal of Immunology, Vol 22, pp. 2573-2578 (1992); "Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes"	
	cr	Langer, Robert, Chemtech, Vol 12, pp.98-105 (1982); "Controlled release of macromolecules"	
	cs	Langer, Robert et al., Jour. of Biomedical Materials Research, Vol 15, pp. 267-277 (1981); "Biocompatibility of polymeric delivery systems for macromolecules"	
	ct	Mackay, Fabienne et al., Jour. of Immunology, Vol 159, pp.3299-3310 (1997); "Cytotoxic Activities of Recombinant Soluble Murine Lymphotoxin-alpha and Lymphotoxin-alpha/beta Complexes"	
	cu	Mauri, Davide et al., Immunity, Vol 8, pp. 21-30 (1998); "LIGHT, a New Member of the TNF Superfamily, and Lymphotoxin alpha are Ligands for Herpesvirus Entry Mediator"	
✓	cv	Miller, Glenn et al., Jour. Experimental Medicine, Vol 178, pp. 211-222 (1993); "Specific Interaction of Lymphocyte Function-associated Antigen 3 with CD2 can Inhibit T Cell Responses"	

Examiner
Signature

Bao Qun Li

Date

Considered

04/15/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **4** of **5**

Complete if Known

Application Number	09/829,031
Filing Date	9 April 2001
First Named Inventor	Jeffrey L. Browning
Group Art Unit	1644
Examiner Name	Bao Qun Li
Attorney Docket Number	A063 US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Beli	cw	Montgomery, Rebecca et al., Cell, Vol 87, pp.427-436 (1996); "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family"	
	cx	Morrison, Sherie, Annual Review of Immunology, Vol. 10, pp.239-265 (1992); "IN VITRO ANTIBODIES: Strategies for Production and Application"	
	cy	Morrison, Sherie et al., Proc. Natl. Academy of Sciences USA, Vol. 81, pp. 6851-6855 (1984); "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains"	
	cz	Pass, Harvey et al., Chest Surgery Clinics of North America, Vol. 5, No. 1, pp. 73-90 (1995); "The Macrophage, TNF, and other Cytokines"	
	ca	Queen, Cary et al., Proc. Natl. Academy of Sciences USA, Vol. 86, pp. 10029-10033 (1989); "A humanized antibody that binds to the interleukin 2 receptor"	
	cab	Roitt et al., Immunology, 3rd ed., pg. 4.8 (1993)	
	cac	Sheehan, Kathleen et al., Jour. of Immunology, Vol. 142, No. 11, pp. 3884-3893 (1989); "Generation and Characterization of Hamster Monoclonal Antibodies that Neutralize Murine Tumor Necrosis Factors"	
	cad	Sidman, Kenneth et al., Biopolymers, Vol. 22, pp. 547-556 (1983); "Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid"	
	cae	Smith, Craig et al., Cell, Vol. 76, pp. 959-962 (1994); "The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death"	
	caf	Trautnecker, Andre et al., Nature, Vol. 339, pp. 68-70 (1989); "Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules"	
	ca	Winter, Greg and Milstein Cesar, Nature, Vol 349, pp. 293-299 (1991); "Man-made antibodies"	

Examiner Signature	<i>Browning</i>	Date Considered	04/14/01
--------------------	-----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Section of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Kn wn

Application Number	09/829,031
Filing Date	9 April 2001
First Named Inventor	Jeffrey L. Browning
Group Art Unit	1644
Examiner Name	Bao Qun Li
Attorney Docket Number	A063 US

(use as many sheets as necessary)

Sheet

5

of

5

Attorney Docket Number

A063 US

[illegible]

**Examiner
Signature**

Das ganze Li

Date _____

Considered

04/15/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**